No Universal Winner: Running Seven Multi-Omics Integrators Head-to-Head on BioMate

If you only remember one thing about multi-omics integration, make it this: there is no universal winner. The two flagship benchmarks — Rappoport & Shamir 2018 and Cantini 2021 — both conclude that the best method depends on the dataset and the question. Our Multi-Omics Integration survey lays out the full method landscape. The practical consequence is what BioMate is built for.

Why "pick one method" is the wrong move

Factor models (MOFA, iCluster) give interpretable, view-attributable factors; network fusion (SNF) is nonlinear and noise-robust; non-negative factorization (intNMF) is best at recovering ground-truth clusters; MCIA is the most consistent all-rounder. Because the leader changes by cohort, the defensible workflow is to run several and compare them with a fair, quantitative harness on your own data — exactly the thing that's tedious to set up by hand.

What BioMate does

• Seven integration methods, one interface. MOFA2, SNF, intNMF, MCIA, MFA, iClusterPlus, and JIVE run end-to-end on AWS Batch (Nextflow), each invoked through a universal CSV interface (features × samples per modality, sample-intersected across views).
• Head-to-head, scored against ground truth. A worked pilot compared them on real chronic lymphocytic leukemia (matched to IGHV status) and TCGA (matched to PAM50), via a reproducible metric harness — and reproduced the literature's message on the user's own data: MOFA2 led on CLL, MCIA led on TCGA. Leader changes by cohort, as the benchmarks predict.
• Modality-specific normalization, automatically. Per-modality normalization (log2-CPM for bulk RNA, log1p-CP10k for scRNA, M-value for methylation, TF-IDF for scATAC, median-centering for proteomics) is applied before integration — fixing the failure mode where one high-magnitude view swamps the rest.

Connecting research to practice

BioMate does not claim a new integration algorithm or a new benchmark result — Cantini already settled "no universal winner." Its contribution is a maintained, your-own-data, cloud platform that turns that finding into a one-command comparison, unifying bulk and (in progress) single-cell/spatial integration under one roof, with a wet-lab loop behind it.

Scope and interpretation

Several modalities (MS proteomics, metabolomics, spatial, CNV, microbiome) have the universal interface in principle but are not yet runtime-validated end-to-end — validation should match the assay, cohort and intended analysis.